Skip to main content
padlock icon - secure page this page is secure

Transient antagonism of anti‐CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines

Buy Article:

$59.00 + tax (Refund Policy)

PI3K inhibitors are evaluated for relapsed and refractory Diffuse large B‐cell lymphoma (DLBCL) patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: PI3K; anti‐CD20; diffuse large B‐cell lymphoma

Document Type: Research Article

Publication date: August 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more